MedTrace Logo

A Study of LY4060874 in Healthy Participants

NCT06709820 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 18 study visits.

Conditions

  • Healthy Participants

Interventions

DRUG

LY4060874

Administered SC

DRUG

LY4060874

Administered IV

DRUG

Placebo

Administered SC

DRUG

Placebo

Administered IV

Sponsors & Collaborators

Principal Investigators

  • 1-877-CTLILLY (1-877-285-4559) or 3176154559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2026-02-20
Completion
2026-02-20
FDA Drug
Yes

Countries

  • United States
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06709820 on ClinicalTrials.gov